Sonova (OTCMKTS:SONVY) Shares Gap Up – Should You Buy?

Sonova Holding (OTCMKTS:SONVY)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $48.28, but opened at $51.2590. Sonova shares last traded at $51.2050, with a volume of 725 shares trading hands.

Analysts Set New Price Targets

Several research analysts have commented on the company. Citigroup reaffirmed a “sell” rating on shares of Sonova in a report on Wednesday, May 13th. Morgan Stanley raised shares of Sonova from an “underweight” rating to an “equal weight” rating in a report on Tuesday, June 23rd. Jefferies Financial Group lowered shares of Sonova from a “hold” rating to a “moderate sell” rating in a research report on Wednesday, March 18th. Finally, BNP Paribas Exane raised shares of Sonova from a “strong sell” rating to a “strong-buy” rating in a report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Sonova Trading Up 2.7%

The business’s 50 day moving average is $48.70 and its two-hundred day moving average is $49.83. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.75 and a quick ratio of 1.43.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.